Kinney Gene G. 4
4 · PROTHENA CORP PUBLIC LTD CO · Filed May 17, 2023
Insider Transaction Report
Form 4
Kinney Gene G.
DirectorPresident and CEO
Transactions
- Sale
Ordinary Shares, par value $0.01 per share
2023-05-17$73.60/sh−19,864$1,462,070→ 27,727 total - Exercise/Conversion
Ordinary Shares, par value $0.01 per share
2023-05-17$29.81/sh+45,000$1,341,450→ 57,793 total - Sale
Ordinary Shares, par value $0.01 per share
2023-05-17$74.49/sh−14,934$1,112,501→ 12,793 total - Sale
Ordinary Shares, par value $0.01 per share
2023-05-17$72.70/sh−10,202$741,721→ 47,591 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-05-17−45,000→ 0 totalExercise: $29.81Exp: 2024-02-04→ Ordinary Shares (45,000 underlying)
Footnotes (6)
- [F1]The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 6, 2023.
- [F2]The transaction was executed in multiple trades in prices ranging from $72.06 to $73.055, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 4 of this Form 4.
- [F3]The transaction was executed in multiple trades in prices ranging from $73.06 to $74.05, inclusive.
- [F4]The transaction was executed in multiple trades in prices ranging from $74.06 to $74.99, inclusive.
- [F5]All shares subject to the option have fully vested.
- [F6]The Reporting Person holds options that give him the right to acquire an aggregate of 2,114,700 shares at exercise prices ranging from $12.15 to $52.97, of which 1,626,365 are currently exercisable, and 488,335 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award.